Results 11 to 20 of about 6,658 (202)
Copper-Mediated Radiosynthesis of [18F]Rucaparib [PDF]
Organic Letters, 2021 The poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib is used in the clinic to treat BRCA-mutated cancers. Herein, we report two strategies to access the 18F-isotopologue of rucaparib by applying a copper-mediated nucleophilic 18F-fluorodeboronation.
Chen, Z +5 more
openaire +5 more sources
The Journal of Organic Chemistry, 2022 A concise total synthesis of rucaparib, an FDA-approved drug for ovarian and prostate cancers, is reported. The Heck reaction of the commercially available aryl iodide with acrylonitrile provided the desired (E)-2-aminocinnamonitrile derivative.
Jinjae Park, Cheol-Hong Cheon
openaire +3 more sources
Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer [PDF]
npj Breast Cancer, 2021 Patients with triple-negative breast cancer (TNBC) who have residual disease after neoadjuvant therapy have a high risk of recurrence. We tested the impact of DNA-damaging chemotherapy alone or with PARP inhibition in this high-risk population.
Maitri Kalra +10 more
doaj +2 more sources
Bioanalytical assay for the quantification of rucaparib in rat plasma using UPLC-MS/MS: development, and validation for interaction with myricetin [PDF]
Frontiers in PharmacologyRucaparib is used to treat ovarian cancer patients with BRCA gene mutations. Myricetin, a flavonol that strongly inhibits CYP450, is widely found in natural plants and has some anticancer properties, with the potential for combination use. However, there
Jingjing Nie +6 more
doaj +2 more sources
Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
Drug Design, Development and Therapy, 2018 Ilaria Colombo, Stephanie Lheureux, Amit Manulal Oza Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada Abstract: Rucaparib is a potent small-molecule inhibitor of poly (ADP ...
Colombo I, Lheureux S, Oza AM
doaj +1 more source
Gynecologic Oncology Reports, 2018 A 56-year old woman with BRCA-associated breast cancer and recurrent ovarian cancer was treated with a poly (ADP-ribose) polymerase enzyme (PARP) inhibitor, rucaparib, in the setting of dialysis-dependence which required dose modification.
Justin A. Harold +2 more
doaj +2 more sources
Nature Communications, 2018 Around 10% of high-grade serous ovarian carcinomas (HGSOC) harbor BRCA1 promoter methylation, but it is uncertain how it predicts response to PARP inhibition.
Olga Kondrashova +30 more
doaj +2 more sources
Targeted treatment of advanced ovarian cancer: spotlight on rucaparib [PDF]
Therapeutics and Clinical Risk Management, 2018 Diana C Pearre, Krishnansu S Tewari Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of California, Irvine Medical Center, Orange, CA, USA Abstract: The last 2 years have ushered in a new era in ovarian cancer ...
Pearre DC, Tewari KS
doaj +2 more sources
Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas [PDF]
Journal of Hematology & Oncology, 2017 Background Trabectedin has recently been approved in the USA and in Europe for advanced soft-tissue sarcoma patients who have been treated with anthracycline-based chemotherapy without success. The mechanism of action of trabectedin depends on the status
Audrey Laroche +7 more
doaj +2 more sources
Rucaparib in metastatic prostate cancer
Cancer Research, Statistics, and Treatment, 2023 Praful Pandey, Ajay Gogia
doaj +2 more sources